# A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia

> **NCT06589817** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Chengdu Kanghong Pharmaceutical Group Co., Ltd.** · enrollment: 376 (estimated)

## Conditions studied

- Acute Schizophrenia

## Interventions

- **DRUG:** Hydrochloride Carliprazine capsules
- **DRUG:** Aripiprazole tablets

## Key facts

- **NCT ID:** NCT06589817
- **Lead sponsor:** Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 376 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06589817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06589817, "A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06589817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*